| Q35035878 | Addictive potential of cannabinoids: the underlying neurobiology |
| Q37387731 | Agonism of the endocannabinoid system modulates binge-like alcohol intake in male C57BL/6J mice: involvement of the posterior ventral tegmental area |
| Q47445865 | Amphetamine elevates nucleus accumbens dopamine via an action potential-dependent mechanism that is modulated by endocannabinoids |
| Q48477201 | Analysis of the effects of cannabinoids on identified synaptic connections in the caudate-putamen by paired recordings in transgenic mice |
| Q92130252 | Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for altered volume striatal glutamate relationships in patients with a history of cannabis use in early psychosis |
| Q35047694 | CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat |
| Q45071453 | CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors. |
| Q34605794 | CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum |
| Q37734568 | Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. |
| Q44885114 | Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. |
| Q26865538 | Classification of H₂O₂as a neuromodulator that regulates striatal dopamine release on a subsecond time scale |
| Q86825974 | Delineation of domains within the cannabinoid CB1 and dopamine D2 receptors that mediate the formation of the heterodimer complex |
| Q62725703 | Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis |
| Q44830723 | Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain |
| Q48678685 | Differential treatment regimen-related effects of HU210 on CB(1) and D(2)-like receptor functionality in the rat basal ganglia. |
| Q43517979 | Direct actions of cannabinoids on synaptic transmission in the nucleus accumbens: a comparison with opioids |
| Q42513159 | Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. |
| Q38593117 | Distribution of the Endocannabinoid System in the Central Nervous System |
| Q22251247 | Dopamine release in the basal ganglia |
| Q42076773 | Effects of the cannabinoid CB1 receptor antagonist rimonabant on distinct measures of impulsive behavior in rats. |
| Q47319226 | Endocannabinoid Actions on Cortical Terminals Orchestrate Local Modulation of Dopamine Release in the Nucleus Accumbens |
| Q39267685 | Endocannabinoid modulation of dopamine neurotransmission |
| Q38098582 | Examining the complex regulation and drug-induced plasticity of dopamine release and uptake using voltammetry in brain slices |
| Q36452302 | Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. |
| Q44051647 | Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids |
| Q44048463 | Inhibition of methamphetamine self-administration in rats by cannabinoid receptor antagonist AM 251. |
| Q33996977 | Inhibition of striatal dopamine release by CB1 receptor activation requires nonsynaptic communication involving GABA, H2O2, and KATP channels |
| Q46384445 | Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. |
| Q44182704 | Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. |
| Q31813503 | Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. |
| Q34430714 | Modulation of transmitter release via presynaptic cannabinoid receptors |
| Q44451116 | Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia |
| Q30493991 | Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. |
| Q48273958 | Neurosystems linking corticolimbic and hypothalamic pathways in energy balance: view from the Chair |
| Q38616780 | Psychostimulant Effect of the Synthetic Cannabinoid JWH-018 and AKB48: Behavioral, Neurochemical, and Dopamine Transporter Scan Imaging Studies in Mice. |
| Q38019926 | Regulation of striatal dopamine release by presynaptic auto- and heteroreceptors |
| Q35869726 | Role of endocannabinoid system in mental diseases |
| Q37228852 | Stress-related factors in cannabis use and misuse: implications for prevention and treatment |
| Q34524803 | Striatal dopamine neurotransmission: regulation of release and uptake |
| Q36358712 | Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate |
| Q38126265 | Tales from the dark side: do neuromodulators of drug withdrawal require changes in endocannabinoid tone? |
| Q35045001 | The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions |
| Q34509920 | The Pharmacological Basis of Cannabis Therapy for Epilepsy |
| Q34267133 | The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ an |
| Q34305854 | The endocannabinoid nervous system: unique opportunities for therapeutic intervention |
| Q35989527 | The endocannabinoid signaling system: a potential target for next-generation therapeutics for alcoholism. |
| Q37038811 | The inverse agonist of CB1 receptor SR141716 blocks compulsive eating of palatable food. |